Cargando…

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol

This analysis provides a comprehensive clinical assessment of the long-term safety of the licensed dose of olodaterol (5 µg once daily [QD] via Respimat(®) inhaler) in patients with chronic obstructive pulmonary disease by exploring the occurrence of acknowledged side effects of long-acting β(2)-ago...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Andrea, Watz, Henrik, Maleki-Yazdi, M. Reza, Bothner, Ulrich, Tetzlaff, Kay, Voß, Florian, McGarvey, Lorcan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653794/
https://www.ncbi.nlm.nih.gov/pubmed/29061968
http://dx.doi.org/10.1038/s41533-017-0059-1